高级搜索

表现为磨玻璃样病变的肺腺癌临床特点与EGFR及K-RAS基因突变的关系

郭天兴, 潘小杰, 欧德彬, 叶明凡

郭天兴, 潘小杰, 欧德彬, 叶明凡. 表现为磨玻璃样病变的肺腺癌临床特点与EGFR及K-RAS基因突变的关系[J]. 肿瘤防治研究, 2014, 41(12): 1313-1317. DOI: 10.3971/j.issn.1000-8578.2014.12.013
引用本文: 郭天兴, 潘小杰, 欧德彬, 叶明凡. 表现为磨玻璃样病变的肺腺癌临床特点与EGFR及K-RAS基因突变的关系[J]. 肿瘤防治研究, 2014, 41(12): 1313-1317. DOI: 10.3971/j.issn.1000-8578.2014.12.013
GUO Tianxing, PAN Xiaojie, OU Debin, YE Mingfan. Relationship of Clinical Characteristics and EGFR, K-RAS Mutation in Lung Adenocarcinoma Patients with Predominant Ground-glass Opacity[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1313-1317. DOI: 10.3971/j.issn.1000-8578.2014.12.013
Citation: GUO Tianxing, PAN Xiaojie, OU Debin, YE Mingfan. Relationship of Clinical Characteristics and EGFR, K-RAS Mutation in Lung Adenocarcinoma Patients with Predominant Ground-glass Opacity[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1313-1317. DOI: 10.3971/j.issn.1000-8578.2014.12.013

表现为磨玻璃样病变的肺腺癌临床特点与EGFR及K-RAS基因突变的关系

详细信息
    作者简介:

    郭天兴(1980-),男,主治医师,硕士,主要从事肺部肿瘤的外科治疗和基础研究

  • 中图分类号: R655.3; R734.2

Relationship of Clinical Characteristics and EGFR, K-RAS Mutation in Lung Adenocarcinoma Patients with Predominant Ground-glass Opacity

  • 摘要: 目的 探讨表现为磨玻璃样病变(GGO)的肺腺癌的临床特点与EGFR及K-RAS基因突变关系。方法 连续选择37例经胸腔镜手术及病理证实为肺腺癌的肺GGO病例,分析其临床特点,检测EGFR与K-RAS基因突变情况,及与各临床因素之间的关系。结果 34例行肺叶切除术,3例行肺楔形切除术,术后病理结果显示:16例为原位腺癌,13例为微浸润腺癌,8例为浸润性腺癌。EGFR 基因突变22例,K-RAS基因突变1例;在单纯型GGO及混合型GGO病例中,EGFR与K-RAS基因突变均无明显差异;在女性、不吸烟病例中EGFR基因突变相较男性及吸烟病例差异具有统计学意义(P<0.05)。结论 EGFR基因在表现为GGO的肺腺癌病例中表现出较高的突变率,为肺GGO病例临床治疗提供了重要参考。
    Abstract: Objective To investigate the relationship between clinical characteristics and EGFR, K-RAS mutation in 37 lung adenocarcinoma patients with predominant ground-glass opacity(GGO). Methods We reviewed the records of 37 lung adenocarcinoma patients with GGO diagnosed by thoracoscopy surgery and postoperative pathology. We analyzed the clinical characteristics and EGFR, K-RAS genic mutation and examined their relationship. Results Among the 37 patients, 34 patients received lobectomy, and the other 3 patients underwent wedge resection of lung. Postoperative pathological diagnosis result was 16 cases of adenocarcinoma in situ (AIS), 13 cases of micro-infiltrating adenocarcinoma(MIA)and 8 cases of infiltrating adenocarcinoma. EGFR mutation was present in 22 cases and K-RAS mutation was observed in one case. There was no significant difference in EGFR and K-RAS mutation between of pGGO cases and mGGO cases, while EGFR mutation were more common in non-smokers and female(P<0.05). Conclusion Lung adenocarcinoma with dominant GGO possess higher EGFR mutations, which could provide definite important reference for clinical molecular targeted therapy for lung GGO patients.
  • [1] Lee SW, Leem CS, Kim TJ, et al. The long-term course of groundglass opacities detected on thin-section computed tomography[J]. Respir Med, 2013,107(6): 904-10.
    [2] Lee KH, Goo JM, Park SJ, et al. Correlation between the size of the solid component on thin-section CT and the invasive component on pathology in small lung adenocarcinomas manifesting as ground-glass nodules[J]. J Thorac Oncol, 2014, 9( 1): 74-82.
    [3] Xu J, Liu CF, Geng LL, et al. Combined score assessment of clinical and imaging features in diagnosis of bronchioloalveolar carcinoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2012, 39(6): 705-9.[徐 健, 刘春芳, 庚俐丽, 等. 临床和影像特征联合评分在细支气 管肺泡癌诊断中的作用评估[J]. 肿瘤防治研究, 2012, 39(6): 70 5-9.]
    [4] Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes[J]. Oncologist, 2011, 16 (6): 87 7-85.
    [5] Meng D, Yuan M, Li X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis[J]. Lung Cancer, 2013, 81(1): 1-10.
    [6] Lin CC, Yang JC. Optimal management of patients with nonsmall cell lung cancer and epidermal growth factor receptor mutations[J].Drugs, 2011, 71(1): 79-88.
    [7] Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J]. PLoS Med, 2005, 2(1): e17.
    [8] Wu JY, Shih JY, Chen KY, et al. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations[J]. Medicine (Baltimore), 2011, 90(3): 159-67.
    [9] Lim HJ, Ahn S, Lee KS, et al. Persistent pure ground-glass opacity lung nodules ≥ 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications[J]. Chest, 2013, 144(4): 12 91-9.
    [10] Cho S, Yang H, Kim K, et al. Pathology and prognosis of persistent stable pure ground-glass opacity nodules after surgical resection[J]. Ann Thorac Surg, 2013, 96(4): 1190-5.
    [11] Song YS, Park CM, Park SJ, et al. Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy[J]. Radiology, 2014, 273(1): 27 6-84.
    [12] Wu YL, Fukuoka M, Mok TS, et al. Tumor response and healthrelated quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with firstline gefitinib: post hoc analyses from the IPASS study[J]. Lung Cancer, 2013, 81(2): 280-7.
    [13] Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011, 6(4): 707-15.
    [14] Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies[J]. Lung Cancer, 2010, 69(3): 272-8.
计量
  • 文章访问数:  2027
  • HTML全文浏览量:  631
  • PDF下载量:  648
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-06-03
  • 修回日期:  2014-08-18
  • 刊出日期:  2014-12-24

目录

    YE Mingfan

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    /

    返回文章
    返回
    x 关闭 永久关闭